MedTrace Logo

EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

NCT00328458 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-05-02

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.

Conditions

  • Central Nervous System Neoplasms
  • Head and Neck Neoplasms

Interventions

DRUG

EPO906 (epothilone B)

Sponsors & Collaborators

Principal Investigators

  • Adam Dicker, MD, PhD · Thomas Jefferson University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2008-05-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328458 on ClinicalTrials.gov